What is the Impact?
Evidence indicates that Nasal High Flow therapy may prevent infants requiring therapy escalation and decrease length of stay in intensive care.
From the Literature
|
"Among infants in the nasal-cannulae group, there was no increase in rates of death or complications and there was a decrease in the rate of nasal trauma, as compared with the CPAP group."
-Manley et al. ( 2013)
|
"It is predicted that the annual cost saving for our 19-bed PICU with 1400 admissions annually would be approximately AUD$1.2 million."
-Mayfield et al .(2014)
|
"The early use of HFNC in a paediatric ward reduced the number of PICU admissions without any serious adverse events having been observed."
-Mayfield et al. (2014)
|
"Following the implementation of the HFNC guideline, the decreased need for intubation was observed across most ARI diagnoses."
-Wing et al. (2014)
|